Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Tomko who wrote (247)	7/1/1998 1:21:00 PM
From: Mac S. Giballa	Read Replies (1) \| Respond to of 318

You're right. I expect positive efficacy results for the ACTION I study, and the safety profile can't be too bad or the ESMC wouldn't have alowwed them to continue- in fact, given the safety issues with ACTION I, there's no way they would have allowed ACTION 1 to continue unless efficacy looked good. So, I tyhink the stock's almost sure to get a big ride this fall-winter. In terms of filing an NDA and getting FDA approval, who knows. No matter what, the second generation products look promising, and I believe that this stock is unbelievably cheap, so I keep buying, I'm averaged down to $4.50 now. Good luck...